See more : Tazmo Co., Ltd. (6266.T) Income Statement Analysis – Financial Results
Complete financial analysis of Ziccum AB (publ) (ZICC.ST) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ziccum AB (publ), a leading company in the Biotechnology industry within the Healthcare sector.
- Shimizu Corporation (SHMUF) Income Statement Analysis – Financial Results
- Storytel AB (publ) (STORY-B.ST) Income Statement Analysis – Financial Results
- South Jersey Industries, Inc (SJIJ) Income Statement Analysis – Financial Results
- Avila Energy Corporation (PTRVF) Income Statement Analysis – Financial Results
- Rakuten Group, Inc. (4755.T) Income Statement Analysis – Financial Results
Ziccum AB (publ) (ZICC.ST)
About Ziccum AB (publ)
Ziccum AB (publ) develops dry powder preparations of biological pharmaceuticals. It develops and commercializes LaminarPace, a spray drying technology that dries chemicals, vaccines, biologics, and drug substances at room temperature. The company was founded in 2017 and is headquartered in Lund, Sweden.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
---|---|---|---|---|---|---|---|
Revenue | 3.75M | 17.00K | 5.00K | 5.00K | 654.00K | 227.00K | 0.00 |
Cost of Revenue | 27.03M | 1.37M | 11.13M | 13.42M | 7.67M | 3.98M | 173.33K |
Gross Profit | -23.29M | -1.36M | -11.12M | -13.42M | -7.02M | -3.75M | -173.33K |
Gross Profit Ratio | -621.46% | -7,976.47% | -222,460.00% | -268,320.00% | -1,073.39% | -1,652.42% | 0.00% |
Research & Development | 0.00 | 0.00 | 208.00K | 209.00K | 208.00K | 209.00K | 0.00 |
General & Administrative | 0.00 | 0.00 | 11.13M | 13.42M | 7.67M | 3.98M | 0.00 |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 27.88M | 27.60M | 11.13M | 13.42M | 7.67M | 3.98M | 0.00 |
Other Expenses | 0.00 | 28.96M | 9.99M | 3.81M | 1.05M | 460.00K | 0.00 |
Operating Expenses | 27.88M | 28.96M | 21.12M | 17.24M | 8.72M | 4.44M | 277.33K |
Cost & Expenses | 27.88M | 28.96M | 21.12M | 17.24M | 8.72M | 4.44M | 450.67K |
Interest Income | 148.00K | 167.00K | 20.00K | 54.00K | 2.00K | 0.00 | 68.00K |
Interest Expense | 0.00 | 167.00K | 20.00K | 54.00K | 2.00K | 361.00K | 0.00 |
Depreciation & Amortization | 1.22M | 1.37M | 634.00K | 182.00K | 43.00K | 227.00K | 277.33K |
EBITDA | -20.34M | -27.58M | -20.27M | -16.84M | -8.68M | -3.98M | -173.33K |
EBITDA Ratio | -542.89% | -138,505.88% | -405,480.00% | -336,880.00% | -1,295.11% | -1,755.07% | 0.00% |
Operating Income | -21.56M | -28.96M | -21.12M | -17.24M | -8.72M | -4.21M | -450.67K |
Operating Income Ratio | -575.39% | -170,323.53% | -422,320.00% | -344,700.00% | -1,333.49% | -1,854.63% | 0.00% |
Total Other Income/Expenses | 148.00K | 167.00K | -20.00K | -54.00K | -2.00K | -361.00K | -68.00K |
Income Before Tax | -21.41M | -28.79M | -21.14M | -17.29M | -8.72M | -4.57M | -518.67K |
Income Before Tax Ratio | -571.44% | -169,341.18% | -422,720.00% | -345,780.00% | -1,333.79% | -2,014.10% | 0.00% |
Income Tax Expense | 0.00 | -334.00K | 20.00K | 54.00K | 2.00K | -1.00K | 0.00 |
Net Income | -21.41M | -28.45M | -21.16M | -17.34M | -8.73M | -4.57M | -518.67K |
Net Income Ratio | -571.44% | -167,376.47% | -423,120.00% | -346,860.00% | -1,334.10% | -2,013.66% | 0.00% |
EPS | -1.54 | -2.05 | -1.91 | -2.05 | -1.45 | -1.27 | -0.19 |
EPS Diluted | -1.54 | -2.05 | -1.91 | -2.05 | -1.45 | -1.27 | -0.19 |
Weighted Avg Shares Out | 13.87M | 13.86M | 11.05M | 8.45M | 6.03M | 3.60M | 2.69M |
Weighted Avg Shares Out (Dil) | 13.87M | 13.86M | 11.05M | 8.45M | 6.03M | 3.60M | 2.69M |
Source: https://incomestatements.info
Category: Stock Reports
What is the impact of the Rights Issue on Ziccum AB’s finances?
Through the Rights Issue, Ziccum may receive initial issue proceeds of approximately SEK 30 million, excluding the additional proceeds that may be received upon exercise of the Warrants that are issued in the Rights Issue.